

# **Antiepileptic Drugs Market Forecasts to 2034 – Global Analysis By Types of Seizures (Partial-onset seizures, Generalized seizures and Other Types of Seizures), Route of Administration (Intravenous, Oral and Other Route of Administrations), Drug Generation, Distribution Channel and By Geography**

<https://marketpublishers.com/r/A79FF4FF4A24EN.html>

Date: April 2026

Pages: 200

Price: US\$ 4,150.00 (Single User License)

ID: A79FF4FF4A24EN

## **Abstracts**

According to Statistics MRC, the Global Antiepileptic Drugs Market is accounted for \$22.3 billion in 2026 and is expected to reach \$36.9 billion by 2034 growing at a CAGR of 6.5% during the forecast period. Epilepsy is a neurological disorder characterized by recurrent and unpredictable seizures, which are caused by abnormal electrical activity in the brain. Antiepileptic drugs work by modulating the electrical activity in the brain, preventing or reducing abnormal impulses that lead to seizures. AEDs stabilize cell membranes, enhance inhibitory neurotransmitters like GABA, block sodium channels, reduce glutamate excitability, or modulate calcium channels.

According to World Health Organization (WHO) on February 09, 2023, 5 million people are diagnosed globally with epilepsy every year. Epilepsy is estimated to affect 49 persons out of every 100,000 in high-income countries every year.

Market Dynamics:

Driver:

Advancements in drug development

Continuous research and development efforts have led to the discovery of new

formulations, novel mechanisms of action, and improved drug delivery systems, revolutionizing the landscape of antiepileptic treatments. The introduction of next-generation antiepileptic drugs has aimed to address limitations associated with traditional therapies, such as adverse side effects and incomplete seizure control. Additionally, advanced formulations, including extended-release versions, offer improved dosing regimens, enhancing patient adherence and overall treatment efficacy. These advancements in drug development propel market demand.

Restraint:

Side effects

Common side effects include dizziness, fatigue, cognitive impairment, and mood alterations, which can significantly impact patients' quality of life. The challenge lies in balancing the therapeutic benefits of seizure control with the tolerability of these side effects. Moreover, the occurrence of adverse reactions may lead to patient dissatisfaction, non-compliance, or discontinuation of treatment, impeding the effectiveness of antiepileptic therapy. These side effects pose a significant restraint, hampering market expansion.

Opportunity:

Rising prevalence of epilepsy

Epilepsy is a neurological disorder characterized by recurrent seizures, and it affects a substantial number of individuals worldwide. The rising prevalence of epilepsy can be attributed to several factors. Firstly, improved diagnostic techniques and increased awareness of epilepsy have contributed to a higher detection rate. As medical knowledge and technological advancements have improved, healthcare professionals are better equipped to diagnose and classify epilepsy accurately. Additionally, awareness campaigns and educational programs have helped spread knowledge about epilepsy symptoms and the importance of early diagnosis, leading to more individuals seeking medical attention.

Threat:

Social stigma

Despite advancements in understanding the neurological condition, societal

misconceptions persist, contributing to reluctance among individuals to seek appropriate treatment. The stigma surrounding epilepsy may lead to under diagnosis and under treatment, as some individuals may avoid disclosing their condition or seeking medical help due to fear of social judgment or discrimination. This unwillingness to discuss epilepsy in public can worsen misinformation, prevent patients from receiving the necessary and efficient treatment that antiepileptic medications provide, and impede patient education. These factors impede market demand.

### Covid-19 Impact

The COVID-19 pandemic has significantly impacted the Antiepileptic Drugs (AEDs) market. Pandemic has underscored the importance of ensuring a resilient healthcare system. Telehealth solutions and remote patient monitoring have gained prominence, providing alternative avenues for epilepsy management. Additionally, the focus on research and development to address neurological complications of COVID-19 has indirectly contributed to advancements in understanding epilepsy and related disorders. Moreover, supply chain disruptions and economic uncertainties have impacted the production and distribution of AEDs, affecting market dynamics.

The third generation segment is expected to be the largest during the forecast period

The third generation segment is estimated to hold the largest share. These drugs, such as lacosamide, eslicarbazepine, and perampanel, exhibit enhanced specificity and efficacy in managing epileptic seizures. Third-generation AEDs often target novel molecular pathways, providing a broader spectrum of action and greater selectivity in modulating neuronal activity. One key feature of third-generation AEDs is their focus on minimizing side effects and drug interactions, thus improving overall tolerability. This is particularly important in enhancing patient adherence to treatment regimens.

The Oral segment is expected to have the highest CAGR during the forecast period

The Oral segment is anticipated to have lucrative growth during the forecast period. Oral administration involves the ingestion of antiepileptic drugs in the form of tablets, capsules, or liquids, allowing for convenient and efficient drug absorption through the gastrointestinal tract. The oral route provides flexibility in drug formulation, enabling the development of extended-release formulations that release the medication gradually over time. This feature helps maintain consistent drug levels in the bloodstream, optimizing therapeutic efficacy and minimizing fluctuations that could trigger seizures.

### Region with largest share:

North America commanded the largest market share during the extrapolated period owing to robust healthcare infrastructure, advanced medical research, and a high prevalence of epilepsy-related disorders. The region's well-established pharmaceutical industry, coupled with substantial investments in research and development, fosters innovation in antiepileptic treatments. Moreover, the presence of key market players and the adoption of cutting-edge technologies contribute to the region's leadership in advancing treatment options.

### Region with highest CAGR:

Asia Pacific is expected to witness profitable growth over the projection period, due to increasing awareness, growing healthcare infrastructure, and a rising incidence of epilepsy-related disorders. A shift towards better diagnostics and increased patient education further fuels the demand for antiepileptic medications in this region. Additionally, with a diverse demographic and a substantial patient base, the region represents a significant growth opportunity for pharmaceutical companies engaged in the development and distribution of antiepileptic drugs.

### Key players in the market

Some of the key players in the Antiepileptic Drugs Market include Eisai Co., Ltd., Novartis AG, Merck KGaA, Teva Pharmaceutical Industries Ltd., AstraZeneca, Abbott, Sanofi, Pfizer Inc., GlaxoSmithKline plc, Dr. Reddy's Laboratories Ltd., Johnson & Johnson Service, Inc., Zogenix, Alkem Labs, SK Biopharmaceuticals and Sun Pharmaceutical Industries Ltd.

### Key Developments:

In June 2023, Pfizer announced a strategic collaboration with Truveta to deliver new safety insights on a continuous basis, using verifiable real-world data at scale.

In January 2021, Novartis announced collaboration with Alnylam to leverage Alnylam's proven, proprietary siRNA technology to inhibit a target discovered at the Novartis Institutes for BioMedical Research, potentially leading to development of a treatment designed to promote the regrowth of functional liver cells and to provide an alternative to transplantation for patients with liver failure.

### Types of Seizures Covered:

Partial-onset seizures

Generalized seizures

Other Types of Seizures

### Route of Administrations Covered:

Intravenous

Oral

Other Route of Administrations

### Drug Generations Covered:

First Generation

Second Generation

Third Generation

### Distribution Channels Covered:

Retail Pharmacies

Hospital Pharmacies

Online Pharmacies

Other Distribution Channels

### Regions Covered:

## North America

US

Canada

Mexico

## Europe

Germany

UK

Italy

France

Spain

Rest of Europe

## Asia Pacific

Japan

China

India

Australia

New Zealand

South Korea

Rest of Asia Pacific

## South America

Argentina

Brazil

Chile

Rest of South America

Middle East & Africa

Saudi Arabia

UAE

Qatar

South Africa

Rest of Middle East & Africa

What our report offers:

Market share assessments for the regional and country-level segments

Strategic recommendations for the new entrants

Covers Market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 2032 and 2034

Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)

Strategic recommendations in key business segments based on the market estimations

Competitive landscaping mapping the key common trends

Company profiling with detailed strategies, financials, and recent developments

Supply chain trends mapping the latest technological advancements

#### Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

##### Company Profiling

Comprehensive profiling of additional market players (up to 3)

SWOT Analysis of key players (up to 3)

##### Regional Segmentation

Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)

##### Competitive Benchmarking

Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

## Contents

### **1 EXECUTIVE SUMMARY**

### **2 PREFACE**

- 2.1 Abstract
- 2.2 Stake Holders
- 2.3 Research Scope
- 2.4 Research Methodology
  - 2.4.1 Data Mining
  - 2.4.2 Data Analysis
  - 2.4.3 Data Validation
  - 2.4.4 Research Approach
- 2.5 Research Sources
  - 2.5.1 Primary Research Sources
  - 2.5.2 Secondary Research Sources
  - 2.5.3 Assumptions

### **3 MARKET TREND ANALYSIS**

- 3.1 Introduction
- 3.2 Drivers
- 3.3 Restraints
- 3.4 Opportunities
- 3.5 Threats
- 3.6 Emerging Markets
- 3.7 Impact of Covid-19

### **4 PORTERS FIVE FORCE ANALYSIS**

- 4.1 Bargaining power of suppliers
- 4.2 Bargaining power of buyers
- 4.3 Threat of substitutes
- 4.4 Threat of new entrants
- 4.5 Competitive rivalry

### **5 GLOBAL ANTIEPILEPTIC DRUGS MARKET, BY TYPES OF SEIZURES**

- 5.1 Introduction
- 5.2 Partial-onset seizures
- 5.3 Generalized seizures
- 5.4 Other Types of Seizures

## **6 GLOBAL ANTIEPILEPTIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION**

- 6.1 Introduction
- 6.2 Intravenous
- 6.3 Oral
- 6.4 Other Route of Administrations

## **7 GLOBAL ANTIEPILEPTIC DRUGS MARKET, BY DRUG GENERATION**

- 7.1 Introduction
- 7.2 First Generation
  - 7.2.1 Carbamazepine
  - 7.2.2 Phenytoin
  - 7.2.3 Valproate
  - 7.2.4 Oxycarbazepine
  - 7.2.5 Ethosuximide
  - 7.2.6 Topiramate
  - 7.2.7 Primidone
  - 7.2.8 Phenobarbital
- 7.3 Second Generation
  - 7.3.1 Pregabalin
  - 7.3.2 Lamotrigine
  - 7.3.3 Levetiracetam
  - 7.3.4 Rufinamide
  - 7.3.5 Eslicarbazepine acetate
  - 7.3.6 Lacosamide
  - 7.3.7 Perampanel
  - 7.3.8 Zonisamide
- 7.4 Third Generation

## **8 GLOBAL ANTIEPILEPTIC DRUGS MARKET, BY DISTRIBUTION CHANNEL**

- 8.1 Introduction
- 8.2 Retail Pharmacies

- 8.3 Hospital Pharmacies
- 8.4 Online Pharmacies
- 8.5 Other Distribution Channels

## **9 GLOBAL ANTIEPILEPTIC DRUGS MARKET, BY GEOGRAPHY**

- 9.1 Introduction
- 9.2 North America
  - 9.2.1 US
  - 9.2.2 Canada
  - 9.2.3 Mexico
- 9.3 Europe
  - 9.3.1 Germany
  - 9.3.2 UK
  - 9.3.3 Italy
  - 9.3.4 France
  - 9.3.5 Spain
  - 9.3.6 Rest of Europe
- 9.4 Asia Pacific
  - 9.4.1 Japan
  - 9.4.2 China
  - 9.4.3 India
  - 9.4.4 Australia
  - 9.4.5 New Zealand
  - 9.4.6 South Korea
  - 9.4.7 Rest of Asia Pacific
- 9.5 South America
  - 9.5.1 Argentina
  - 9.5.2 Brazil
  - 9.5.3 Chile
  - 9.5.4 Rest of South America
- 9.6 Middle East & Africa
  - 9.6.1 Saudi Arabia
  - 9.6.2 UAE
  - 9.6.3 Qatar
  - 9.6.4 South Africa
  - 9.6.5 Rest of Middle East & Africa

## **10 KEY DEVELOPMENTS**

- 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
- 10.2 Acquisitions & Mergers
- 10.3 New Product Launch
- 10.4 Expansions
- 10.5 Other Key Strategies

## **11 COMPANY PROFILING**

- 11.1 Eisai Co., Ltd.
- 11.2 Novartis AG
- 11.3 Merck KGaA
- 11.4 Teva Pharmaceutical Industries Ltd.
- 11.5 AstraZeneca
- 11.6 Abbott
- 11.7 Sanofi
- 11.8 Pfizer Inc.
- 11.9 GlaxoSmithKline plc
- 11.10 Dr. Reddy's Laboratories Ltd.
- 11.11 Johnson & Johnson Service, Inc.
- 11.12 Zogenix
- 11.13 Alkem Labs
- 11.14 SK Biopharmaceuticals
- 11.15 Sun Pharmaceutical Industries Ltd.

## List Of Tables

### LIST OF TABLES

Table 1 Global Antiepileptic Drugs Market Outlook, By Region (2023–2034) (\$MN)

Table 2 Global Antiepileptic Drugs Market Outlook, By Types of Seizures (2023–2034) (\$MN)

Table 3 Global Antiepileptic Drugs Market Outlook, By Partial-onset seizures (2023–2034) (\$MN)

Table 4 Global Antiepileptic Drugs Market Outlook, By Generalized seizures (2023–2034) (\$MN)

Table 5 Global Antiepileptic Drugs Market Outlook, By Other Types of Seizures (2023–2034) (\$MN)

Table 6 Global Antiepileptic Drugs Market Outlook, By Route of Administration (2023–2034) (\$MN)

Table 7 Global Antiepileptic Drugs Market Outlook, By Intravenous (2023–2034) (\$MN)

Table 8 Global Antiepileptic Drugs Market Outlook, By Oral (2023–2034) (\$MN)

Table 9 Global Antiepileptic Drugs Market Outlook, By Other Route of Administrations (2023–2034) (\$MN)

Table 10 Global Antiepileptic Drugs Market Outlook, By Drug Generation (2023–2034) (\$MN)

Table 11 Global Antiepileptic Drugs Market Outlook, By First Generation (2023–2034) (\$MN)

Table 12 Global Antiepileptic Drugs Market Outlook, By Carbamazepine (2023–2034) (\$MN)

Table 13 Global Antiepileptic Drugs Market Outlook, By Phenytoin (2023–2034) (\$MN)

Table 14 Global Antiepileptic Drugs Market Outlook, By Valproate (2023–2034) (\$MN)

Table 15 Global Antiepileptic Drugs Market Outlook, By Oxycarbazepine (2023–2034) (\$MN)

Table 16 Global Antiepileptic Drugs Market Outlook, By Ethosuximide (2023–2034) (\$MN)

Table 17 Global Antiepileptic Drugs Market Outlook, By Topiramate (2023–2034) (\$MN)

Table 18 Global Antiepileptic Drugs Market Outlook, By Primidone (2023–2034) (\$MN)

Table 19 Global Antiepileptic Drugs Market Outlook, By Phenobarbital (2023–2034) (\$MN)

Table 20 Global Antiepileptic Drugs Market Outlook, By Second Generation (2023–2034) (\$MN)

Table 21 Global Antiepileptic Drugs Market Outlook, By Pregabalin (2023–2034) (\$MN)

Table 22 Global Antiepileptic Drugs Market Outlook, By Lamotrigine (2023–2034) (\$MN)

Table 23 Global Antiepileptic Drugs Market Outlook, By Levetiracetam (2023–2034) (\$MN)

Table 24 Global Antiepileptic Drugs Market Outlook, By Rufinamide (2023–2034) (\$MN)

Table 25 Global Antiepileptic Drugs Market Outlook, By Eslicarbazepine acetate (2023–2034) (\$MN)

Table 26 Global Antiepileptic Drugs Market Outlook, By Lacosamide (2023–2034) (\$MN)

Table 27 Global Antiepileptic Drugs Market Outlook, By Perampanel (2023–2034) (\$MN)

Table 28 Global Antiepileptic Drugs Market Outlook, By Zonisamide (2023–2034) (\$MN)

Table 29 Global Antiepileptic Drugs Market Outlook, By Third Generation (2023–2034) (\$MN)

Table 30 Global Antiepileptic Drugs Market Outlook, By Distribution Channel (2023–2034) (\$MN)

Table 31 Global Antiepileptic Drugs Market Outlook, By Retail Pharmacies (2023–2034) (\$MN)

Table 32 Global Antiepileptic Drugs Market Outlook, By Hospital Pharmacies (2023–2034) (\$MN)

Table 33 Global Antiepileptic Drugs Market Outlook, By Online Pharmacies (2023–2034) (\$MN)

Table 34 Global Antiepileptic Drugs Market Outlook, By Other Distribution Channels (2023–2034) (\$MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.

## I would like to order

Product name: Antiepileptic Drugs Market Forecasts to 2034 – Global Analysis By Types of Seizures (Partial-onset seizures, Generalized seizures and Other Types of Seizures), Route of Administration (Intravenous, Oral and Other Route of Administrations), Drug Generation, Distribution Channel and By Geography

Product link: <https://marketpublishers.com/r/A79FF4FF4A24EN.html>

Price: US\$ 4,150.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/A79FF4FF4A24EN.html>